EGFR and neoplasm: These data highlight the potential value for clinical management of analysing mutations which may not be perceived as “actionable”, such as mutations in the tumour suppressor TP53, and suggests that the genetic context of an EGFR‐mutant tumour may determine its dependence on the EGFR and/or other pathways and predict sensitivity or resistance to EGFR‐directed treatment.